A BILL 
To direct the Inspector General of the Department of Health 
and Human Services to investigate and report on the 
Vaccine Adverse Event Reporting System, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Justice for Vaccine 
4
Victims Act of 2022’’. 
5
16:42 Apr 04, 2022
H7308
2 
•HR 7308 IH
SEC. 2. INVESTIGATION ON VACCINE ADVERSE EVENT RE-
1
2
(a) IN GENERAL.—The Inspector General of the De-
3
partment of Health and Human Services shall investigate 
4
the Vaccine Adverse Event Reporting System of the Cen-
5
ters for Disease Control and Prevention and Food and 
6
Drug Administration. 
7
(b) REQUIRED QUESTIONS.— 
8
(1) INDIVIDUALS.— 
9
(A) In conducting the investigation under 
10
subsection (a), the Inspector General of the De-
11
partment of Health and Human Services shall 
12
ask every individual who reported an adverse 
13
event to a COVID–19 vaccine at a minimum 
14
the following questions: 
15
(i) Which COVID–19 vaccine did you 
16
receive? 
17
(ii) Which vaccine did you receive as 
18
a booster shot? 
19
(iii) Do you have any allergies or pre-
20
existing conditions? 
21
(iv) Was the adverse event mild, such 
22
as minor pain or swelling, or severe, such 
23
as leading to hospitalization, disability, or 
24
death? 
25
16:42 Apr 04, 2022
H7308
3 
•HR 7308 IH
(v) Can you describe in detail the 
1
symptoms of the adverse event? 
2
(vi) In detail, can you describe any 
3
health problems you believe were caused by 
4
the adverse event? 
5
(vii) Are you aware of any other indi-
6
viduals within your community who had a 
7
similar adverse event? 
8
(viii) When receiving a vaccination did 
9
you notice anything suspicious regarding 
10
how the vaccination was administered? 
11
(ix) How soon after the adverse event 
12
did you report it to the Vaccine Adverse 
13
Event Reporting System? 
14
(x) Did you seek compensation for the 
15
adverse 
event 
through 
the 
Counter-
16
measures Injury Compensation Program? 
17
(xi) Would you be willing to testify 
18
under oath to a congressional committee? 
19
(B) If an individual described in subpara-
20
graph (A) is deceased, the Inspector General of 
21
the Department of Health and Human Services 
22
shall ask one or more of the individual’s imme-
23
diate family members to answer (on the individ-
24
16:42 Apr 04, 2022
H7308
4 
•HR 7308 IH
ual’s behalf) the questions listed in subpara-
1
graph (A). 
2
(2) MANUFACTURERS.—In conducting the in-
3
vestigation under subsection (a), the Inspector Gen-
4
eral of the Department of Health and Human Serv-
5
ices shall ask each manufacturer of a COVID–19 
6
vaccine that is distributed in the United States, at 
7
a minimum, the following questions and requests: 
8
(A) What are the ingredients in your 
9
COVID–19 vaccine or vaccines distributed in 
10
the United States? 
11
(B) Can you provide all information relat-
12
ing to your manufacturing methods and your 
13
data on the stability and safety of the product? 
14
(C) What is the address of each of your lo-
15
cations involved in the manufacture of the vac-
16
cines? 
17
(D) Did you include labeling of the vaccine 
18
or vaccines containing a specific statement de-
19
scribing how suspected adverse events can be 
20
reported? 
21
(E) Can you provide substantive evidence 
22
you have followed all Food and Drug Adminis-
23
tration guidance regarding product safety? 
24
16:42 Apr 04, 2022
H7308
5 
•HR 7308 IH
(F) How many adverse events did you re-
1
port to the Vaccine Adverse Event Reporting 
2
System pursuant to section 2125 of the Public 
3
Health Service Act (42 U.S.C. 300aa–25) or 
4
other applicable law? 
5
(G) Are you conducting your own internal 
6
review of any adverse events caused by the vac-
7
cine or vaccines? 
8
(H) Are you ensuring that all public state-
9
ments regarding vaccine safety are accurate? 
10
(I) Are you limiting reporting data regard-
11
ing adverse events? 
12
(J) Would you be willing to direct rep-
13
resentatives to testify under oath to a congres-
14
sional committee? 
15
(3) HEALTH CARE PROVIDERS.—In conducting 
16
the investigation under subsection (a), the Inspector 
17
General of the Department of Health and Human 
18
Services shall ask a representative sample of health 
19
care providers, at a minimum, the following ques-
20
tions: 
21
(A) How many adverse events did you re-
22
port to the Vaccine Adverse Event Reporting 
23
System pursuant to section 2125 of the Public 
24
16:42 Apr 04, 2022
H7308
6 
•HR 7308 IH
Health Service Act (42 U.S.C. 300aa–25) or 
1
other applicable law? 
2
(B) What kind of compensation does your 
3
facility receive for vaccine administration and 
4
from which source or sources? 
5
(C) Is your facility keeping a record of any 
6
increase in hospitalization rates for individuals 
7
with adverse events following vaccination? 
8
(D) How many severe adverse events has 
9
your facility encountered? 
10
(E) How many mild adverse events has 
11
your facility encountered? 
12
(F) Has your facility determined if adverse 
13
events are caused by an immune response to 
14
the vaccine? 
15
(G) Is your facility keeping a record of any 
16
problems with vaccine administration? 
17
(H) Is your facility keeping a record of all 
18
breakthrough cases of COVID–19 in fully vac-
19
cinated patients? 
20
(I) Has your facility terminated any health 
21
care professionals who are opposed to vaccine 
22
mandates or who have raised questions regard-
23
ing adverse events? 
24
16:42 Apr 04, 2022
H7308
7 
•HR 7308 IH
(J) Would you be willing to direct rep-
1
resentatives of your facility to testify under 
2
oath to a congressional committee? 
3
(c) REPORTS.— 
4
(1) REPORT ON VAERS.— 
5
(A) IN
GENERAL.—Not later than 3 
6
months after the date of enactment of this Act, 
7
the Inspector General of the Department of 
8
Health and Human Services shall— 
9
(i) complete the investigation under 
10
subsection (a); and 
11
(ii) publish a report on the results of 
12
such investigation. 
13
(B) CONTENTS.—The report under sub-
14
paragraph (A)(ii) shall include the following: 
15
(i) A list of all reported COVID–19 
16
vaccine related deaths and injuries in 
17
chronological order. 
18
(ii) Transcripts of all interviews con-
19
ducted by the Inspector General pursuant 
20
to this section with an individual described 
21
in subsection (b)(1), a manufacturer de-
22
scribed in subsection (b)(2), or a health 
23
care provider described in subsection 
24
(b)(3). 
25
16:42 Apr 04, 2022
H7308
8 
•HR 7308 IH
(iii) A list of recommendations on how 
1
the Centers for Disease Control and Pre-
2
vention and the Food and Drug Adminis-
3
tration can strengthen the Vaccine Adverse 
4
Event Reporting System to be a more reli-
5
able method of obtaining information 
6
about adverse events. 
7
(iv) A determination on whether the 
8
Centers for Disease Control and Preven-
9
tion or the Food and Drug Administration 
10
is hiding data regarding adverse events. 
11
(v) A determination on whether the 
12
Food and Drug Administration is sup-
13
pressing data on the effectiveness of 
14
monoclonal antibodies that are used to 
15
treat COVID–19. 
16
(vi) Recommendations on further ac-
17
tions the Congress can take when con-
18
ducting oversight regarding data collection 
19
by the Centers for Disease Control and 
20
Prevention and the Food and Drug Admin-
21
istration. 
22
(vii) A determination on whether ad-
23
verse events are common or rare following 
24
administration of a COVID–19 vaccine. 
25
16:42 Apr 04, 2022
H7308
9 
•HR 7308 IH
(viii) A determination of any causal 
1
relationship between any COVID–19 vac-
2
cine and specific adverse events using clin-
3
ical, laboratory, or epidemiologic evidence. 
4
(ix) A determination on whether ad-
5
verse events are intrinsic to the COVID–19 
6
vaccine (meaning provoked by the immune 
7
response caused by the vaccine) or related 
8
to faulty production or administration of 
9
the COVID–19 vaccine. 
10
(2) REPORT ON INVESTIGATION.— 
11
(A) IN
GENERAL.—Not later than 6 
12
months after publishing the report required by 
13
paragraph (1)(A)(ii), the Inspector General of 
14
the Department of Health and Human Services 
15
shall submit to the relevant congressional com-
16
mittees a report on the implementation of this 
17
section. 
18
(B) CONTENTS.—The report under sub-
19
paragraph (A) shall— 
20
(i) specify, of the amount authorized 
21
by subsection (c)(1) to be appropriated to 
22
carry out this section, the total amount ob-
23
ligated and expended; and 
24
16:42 Apr 04, 2022
H7308
10 
•HR 7308 IH
(ii) describe how such amount was 
1
used. 
2
(d) SUBPOENA POWER.—The Inspector General of 
3
the Department of Health and Human Services may, pur-
4
suant to authorities vested in the Inspector General by 
5
other applicable law, issue subpoenas requiring the attend-
6
ance and testimony of witnesses and the production of any 
7
evidence relating to any matter under investigation pursu-
8
ant to this section. 
9
(e) AUTHORIZATION OF APPROPRIATIONS.— 
10
(1) IN GENERAL.—To carry out this section, 
11
there is authorized to be appropriated $100,000,000 
12
for the period beginning on the date of enactment of 
13
this Act and ending on the date of submission of the 
14
report required by subsection (b)(2). 
15
(2) OFFSET.— 
16
(A) REPEAL OF DEDUCTION FOR CERTAIN 
17
STATE AND LOCAL, ETC., TAXES OF INDIVID-
18
UALS.—Section 164(b)(6) of the Internal Rev-
19
enue Code of 1986 is amended by— 
20
(i) striking ‘‘and before January 1, 
21
2026—’’ and all that follows through ‘‘a 
22
separate return).’’ and inserting ‘‘para-
23
graphs (1), (2), and (3) of subsection (a) 
24
16:42 Apr 04, 2022
H7308
11 
•HR 7308 IH
and paragraph (5) of this subsection shall 
1
not apply.’’; and 
2
(ii) by striking ‘‘FOR TAXABLE YEARS 
3
2018 THROUGH 2025’’ in the heading there-
4
of. 
5
(B) EFFECTIVE DATE.—The amendments 
6
made by this paragraph shall apply to taxable 
7
years beginning after the date of the enactment 
8
of this Act. 
9
SEC. 3. TERMINATION OF COVID–19 PUBLIC HEALTH EMER-
10
GENCY DECLARATION UNDER PUBLIC READI-
11
NESS 
AND 
EMERGENCY 
PREPAREDNESS 
12
(PREP) ACT. 
13
(a) IN GENERAL.—The Secretary of Health and 
14
Human Services shall— 
15
(1) not later than 3 months after the date of 
16
enactment of this Act, terminate the public health 
17
emergency declaration issued in connection with 
18
COVID–19 pursuant to section 319F–3 of the Pub-
19
lic Health Service Act (42 U.S.C. 247d–6d); and 
20
(2) not reissue any such declaration or any sub-
21
stantially similar declaration. 
22
(b) CORRESPONDING TERMINATION
OF LIABILITY 
23
PROTECTION.—No immunity from suit and liability under 
24
section 319F–3 of the Public Health Service Act (42 
25
16:42 Apr 04, 2022
H7308
12 
•HR 7308 IH
U.S.C. 247d–6d) shall apply with respect to the adminis-
1
tration to or the use by an individual of a covered counter-
2
measure if— 
3
(1) the immunity relies on a declaration de-
4
scribed in subsection (a); and 
5
(2) the administration or use occurs after such 
6
declaration is terminated, 
7
except that the Secretary of Health and Human Services, 
8
pursuant to section 319F–3(b)(3)(B) of such Act (42 
9
U.S.C. 247d–6d(b)(3)(B)), shall specify an additional im-
10
munity period of 3 months for the manufacturer to ar-
11
range for disposition of the covered countermeasure and 
12
for covered persons to take such other actions as may be 
13
appropriate to limit administration or use of the covered 
14
countermeasure, as described in clauses (i) and (ii) of such 
15
section 319F–3(b)(3)(B). 
16
Æ 
16:42 Apr 04, 2022
H7308
